Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MDXG
BuyFLAGMiMedx Group, Inc. · Healthcare · United States · $622M · Avg Vol: $6M/d
MiMedx has strong quality Q74 and value V63, but momentum at M35 is well below the calibrated floor, and a positive revision is not accepted corroboration, so stage one fails.
COMPANY DESCRIPTION
MiMedx Group, Inc. is a biopharmaceutical company specializing in the development and commercialization of regenerative and therapeutic biologics derived from human placental tissue. Its proprietary allograft products, including AmnioFix and EpiFix, hold a leading position in advanced wound care and surgical recovery markets, backed by extensive clinical evidence and patent-protected processing technologies. MiMedx is a pioneer in regenerative medicine, offering innovative solutions for complex medical conditions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 267.8M | 321.5M | 348.9M | 418.6M | 16.1% | 355.2M | 269.8M | 303.3M | -14.9% |
| EPS | -0.33 | 0.40 | 0.29 | 0.33 | -9.2% | 0.04 | — | — | — |
| Shares | 113.7M | 146.2M | 146.9M | 148.1M | +30.2% | 145.8M | — | — | — |
| Debt | 48.6M | 49.1M | 18.8M | 18.0M | -28.2% | 17.2M | — | — | — |
| Equity | -18.0M | 142.7M | 193.1M | 256.5M | 34.1% | — | — | — | — |
| Op CF | -17.9M | 26.8M | 66.2M | 74.0M | 66.2% | 46.1M | — | — | — |
| Inv CF | -2.7M | -2.2M | -9.6M | -6.9M | — | — | — | — | — |
| Fin CF | -0.6M | -8.6M | -34.2M | -5.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MDXG are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MDXG | MiMedx Group, Inc.(you) | $622M | 70 | Buy |
| TBPH | Theravance Biopharma, Inc. | $883M | 71 | Buy |
| FENC | Fennec Pharmaceuticals Inc. | $400M | 61 | Hold |
| MGTX | MeiraGTx Holdings plc | $1.4B | 71 | Buy |
| ZVRA | Zevra Therapeutics, Inc. | $692M | 87 | Strong Buy |
| FTRE | Fortrea Holdings Inc. | $1.7B | 70 | Buy |
| QTTB | Q32 Bio Inc. | $487M | 88 | Strong Buy |
| ABUS | Arbutus Biopharma Corporation | $1.0B | 84 | Strong Buy |
| MNPR | Monopar Therapeutics Inc. | $747M | 50 | Hold |
| AGEN | Agenus Inc. | $345M | 84 | Strong Buy |
Peer medians: ROE -25.8% · P/E 29.5x · Gross margin 58.7%